Small study results raise Sutent heart failure concerns

Share this article:

Small study results released at yesterday's Genitourinary Cancers Symposium in San Francisco showed that 15% patients taking Pfizer's Sutent suffered heart failure, a rate higher than in clinical trials of the drug.

Seven of 48 patients receiving Sutent experienced heart failure, according to the study lead by researcher Dr. Melinda Telli of the Stanford University School of Medicine.

The small 48-patient study, which tracked patients from 2004 to 2007, was not a clinical trial.

Telli said that although the study was limited by the numbers it is possible that the true incidence of heart failure could be even higher. She advised that doctors should conduct routine monitoring of Sutent patients to detect problems with heart function.

Barbara Ryan, analyst for Deutsche Bank North America, said in a published report that results of the study “probably warrant further investigation,” but it's difficult to draw any conclusions, “given the small size of the study.”

Sutent is approved by the FDA in treatment of cancer of the kidney and digestive system. Sales of the drug for 2007 were $581 million, up 166% from $219 million the previous year.

A Pfizer spokeswoman told website that the company has not had an opportunity to review the data and stressed that cardiovascular events are acknowledged on Sutent safety labels, along with recommendations for monitoring patients with cardiac risk factors.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...